Head and Neck Cancer

ClinicalAugust 15, 2026

Study on Durvalumab and Tremelimumab with SBRT for Metastatic Head and Neck Carcinomas

A clinical trial is assessing the combination of Durvalumab, Tremelimumab, and SBRT for metastatic head and neck squamous cell carcinomas, led by CHUM and in collaboration with AstraZeneca.

ClinicalAugust 14, 2026

Phase I/II Trial of Ficerafusp Alfa with Pembrolizumab and SBRT in HPV-Negative HNSCC

An open-label phase I/II trial is underway to evaluate ficerafusp alfa, pembrolizumab, and SBRT in patients with high-risk, locoregionally advanced HPV-negative HNSCC.

StrategyAugust 13, 2026

Cost-effectiveness of Finotonlimab in R/M HNSCC Treatment in China

The SCT-I10A-B301 trial shows finotonlimab combined with chemotherapy for R/M HNSCC has an ICER of $112,384.47/QALY, exceeding China's WTP threshold.

ClinicalAugust 9, 2026

Financial Compass Trial Aims to Alleviate Financial Hardship in Head and Neck Cancer Patients

The Financial Compass trial is assessing the effectiveness of a financial intervention compared to usual care for head and neck cancer patients facing financial hardship.

ClinicalAugust 8, 2026

Study on Tarceva and RADPLAT in Head and Neck Cancer Shows Promise

The study aims to evaluate the safety and effectiveness of Tarceva combined with RADPLAT in treating locally advanced Head and Neck Squamous Cell Carcinoma.

ClinicalAugust 4, 2026

Study on ctDNA and HPV DNA Detection in High-risk Head and Neck Cancer Initiated

A study is underway to evaluate the feasibility of real-time detection of ctDNA and HPV DNA in patients with high-risk locally advanced head and neck squamous cell carcinoma.

ClinicalJuly 26, 2026

Phase II Trial Evaluates Chemo and Chemo-Immunotherapy for Advanced Head and Neck Cancer

A phase II trial is testing the addition of chemotherapy or chemo-immunotherapy to standard salvage surgery for PD-L1 positive head and neck squamous cell carcinoma.

ClinicalJuly 20, 2026

Trial on Far Infrared Rays and TENS for Head and Neck Cancer Patients

A clinical trial is evaluating the efficacy of far infrared radiation therapy and transcutaneous electrical nerve stimulation in reducing side effects for head and neck cancer patients undergoing chemoradiotherapy.

ClinicalJuly 12, 2026

Phase II Trial Evaluates Radiation Therapy Plus Cisplatin for Head and Neck Cancer

A phase II trial is investigating the efficacy of radiation therapy with or without cisplatin in patients with stage III-IVA squamous cell carcinoma of the head and neck post-surgery.

ClinicalJuly 9, 2026

Phase II/III Trial Evaluates Docetaxel-Cetuximab with Atezolizumab in High-Risk Head and Neck Cancer

A phase II/III trial is assessing the efficacy of combining radiation therapy with docetaxel, cetuximab, and atezolizumab in high-risk head and neck cancer patients.

ClinicalJuly 8, 2026

Study on MyCap App for Monitoring Radiation Dermatitis in Head and Neck Cancer Patients

A study is underway to evaluate the MyCap mobile app for tracking radiation-induced skin rash in head and neck cancer patients.

ClinicalJuly 5, 2026

Neoadjuvant Therapy Trial for Head and Neck Squamous Cell Carcinoma Initiated

A clinical trial is evaluating the safety and tolerability of a combination of immune-targeted therapy and lysogenic HSV-based virotherapy in patients with resectable head and neck squamous cell carcinoma.

ClinicalJune 28, 2026

Durvalumab and Cetuximab Combination Trial for Head and Neck Cancer

A clinical trial is underway to evaluate the efficacy of durvalumab combined with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

ClinicalJune 28, 2026

Phase 2 Trial of SX-682 and Docetaxel in Advanced Head and Neck and Prostate Cancers

A new trial is underway to evaluate the combination of SX-682 and docetaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma and advanced prostate cancer.

ClinicalJune 26, 2026

Phase II/III Trial Compares Weekly vs. Every Three Weeks Cisplatin in Advanced Head and Neck Cancer

A phase II/III trial is comparing the tolerability and efficacy of weekly versus every three weeks cisplatin combined with radiation in advanced head and neck cancer.

ClinicalJune 24, 2026

Phase II Trial of Axelopran with Pembrolizumab in Head and Neck Cancer

A Phase II trial is underway to evaluate axelopran's safety and efficacy with pembrolizumab in R/M HNSCC patients.

Companies

Assets

Recent signals